home / stock / ngenf / ngenf news

NGENF News and Press, NervGen Pharma Corp From 04/08/21

Stock Information
Company Name: NervGen Pharma Corp
Stock Symbol: NGENF
Market: OTC
Website: nervgen.com
Menu
NGENF NGENF Quote NGENF Short NGENF News NGENF Articles NGENF Message Board
Get NGENF Alerts

News, Short Squeeze, Breakout and More Instantly...
NGENF - NervGen Pharma Reports 2020 Year End Results

Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported i...
NGENF - NervGen Pharma's NVG-291 wins EMA 'Orphan' status

NervGen Pharma (NGENF) announces that the European Medicines Agency has granted "Orphan" designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor.The EMA status provides NervGen with multiple ...

NGENF - NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced th...

NGENF - NervGen Pharma Provides Regulatory Update on Development Program For NVG-291

Plans to Dose First Human Subjects in Phase 1 in Q2 2021 Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve dam...
NGENF - NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announc...

NGENF - NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the...

NGENF - NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that...
NGENF - NervGen Pharma Engages CRO for Phase 1 Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announ...

NGENF - NervGen Pharma reports Q3 results

NervGen Pharma (NGENF): Q3 GAAP EPS of -$0.06.The net cash burn for Q3 2020 from operating activities was ~$1.2M.Cash balance of $7.7MPress Release For further details see: NervGen Pharma reports Q3 results

NGENF - NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its...
Previous 10 Next 10